COVID-19 leads to the involvement of the respiratory tract causing a severe acute respiratory syndrome, SARs-Cov-2 1,2 . This can predispose to thrombotic diseases, both arterial and venous, due to the excess of inflammatory reaction, platelet activation, endothelial dysfunction, and stasis 1,3 . Thrombotic events can be diverse: venous thromboembolism 4,5 , pulmonary embolism 2,6 , and even disseminated intravascular coagulation 2 .Thinking about the pathophysiological importance of these thrombotic events for the appearance of severe forms, we raised the following question: did anticoagulation have a role in the prevention of thrombotic events in SARS-Cov-2? Would this role be greater in patients with countless patients, who generally progress to more severe forms? Are patients who are already using anticoagulants better protected from these severe forms of this disease? The following is a clinical case that illustrates this hypothesis:• Patient Male patient, 66 years old, with diarrhea and prostration initially, later evolving with fever, headache, and dry cough. Comorbidities: obesity, systemic arterial hypertension, Diabetes Mellitus, heart failure, sleep apnea, and atrial fibrillation (AF). Using medications including Eliquis 5 mg twice daily to prevent thromboembolic events secondary to AF.Due to symptoms and the current context of the pandemic, the patient sought emergency care, where an RT-PCR test was performed for COVID 19, which was positive. As the patient was stable from a respiratory and hemodynamic point of view, without the need for oxygen supplementation, symptomatic treatment was prescribed and guided observation at home. The patient evolved uneventfully with complete clinical improvement 15 days after the onset of symptoms.